APA (7th ed.) Citation

Hu, G., Zuo, Y., Zhang, X., Wang, Y., Xu, L., Xin-lin, H., . . . Xiao-jun, H. (2026). Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. Leukemia & Lymphoma, 67(4), 846. https://doi.org/10.1080/10428194.2025.2611117

Chicago Style (17th ed.) Citation

Hu, Guan-hua, Ying-xi Zuo, Xiao-hui Zhang, Yu Wang, Lan-ping Xu, Hou Xin-lin, Yi-fei Cheng, and Huang Xiao-jun. "Efficacy and Safety of Inotuzumab Ozogamicin as the Definitive Therapeutic Option Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Relapsed/refractory B-cell Acute Lymphoblastic Leukemia." Leukemia & Lymphoma 67, no. 4 (2026): 846. https://doi.org/10.1080/10428194.2025.2611117.

MLA (9th ed.) Citation

Hu, Guan-hua, et al. "Efficacy and Safety of Inotuzumab Ozogamicin as the Definitive Therapeutic Option Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Relapsed/refractory B-cell Acute Lymphoblastic Leukemia." Leukemia & Lymphoma, vol. 67, no. 4, 2026, p. 846, https://doi.org/10.1080/10428194.2025.2611117.